Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suke Ganmao is an oral fixed-dose combination medication developed and manufactured by Dalian Aosen Pharmaceutical (and its subsidiary Dalian Mingsen Pharmaceutical) for the symptomatic relief of the common cold and influenza. The formulation typically consists of paracetamol (acetaminophen), amantadine hydrochloride, chlorpheniramine maleate, caffeine, and artificial bezoar. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis, while amantadine hydrochloride provides antiviral activity against influenza A viruses. Chlorpheniramine maleate acts as an H1-antihistamine to reduce nasal congestion and sneezing, and caffeine is included to counteract the sedative effects of the antihistamine and enhance the analgesic properties of paracetamol. Artificial bezoar is a traditional component used for its antipyretic and sedative effects. It is approved in China as an over-the-counter (OTC) treatment for respiratory symptoms including fever, headache, and sore throat.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Suke Ganmao.